SecBot SecBot
Insider Cluster (3 insiders) ·Filed Jun 15, 2026

LGND

LIGAND PHARMACEUTICALS INC
NEUTRAL
Impact 2/10
Horizonimmediate Processed5mo ago
Insider cluster: 2 insiders, $2.0M total
Actionable Insight • Neutral

The insider selling is immaterial in size and involves only directors, not C-suite. No bearish signal. Monitor for any future C-suite selling or a material increase in dollar volume before adjusting stance.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$255.25
T+0 close · Jun 15, 2026 · via day close
Latest settled
+13.32%
T+60 · $289.25
Vs SPY
+12.32%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 16 $255.25entry
  2. T+1 · 5mo ago +3.09%α +4.34% · $263.14
  3. T+5 · 5mo ago +9.48%α +11.71% · $279.44
  4. T+20 · 4mo ago +17.91%α +17.71% · $300.97
  5. T+60 · 2mo ago +13.32%α +12.32% · $289.25
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Three directors sold a total of ~$1.95M in LGND shares over a 7-day window, representing only ~0.04% of the company's $5.1B market cap. All sellers are non-C-suite directors, and the sales are trivial relative to market cap, indicating routine portfolio diversification rather than informed selling.

Key Financial Metrics

Direction
selling
Total Value
$1.9M
Insiders
3

Key Facts

  • Total insider sales of ~$1.95M across 3 directors (Haas, Aryeh, Lamattina) from June 10-12, 2026.
  • Sales represent ~0.04% of LGND's $5.1B market cap, well below the 0.1% materiality threshold.
  • No C-suite executives (CEO, CFO, etc.) participated in the cluster; all sellers are directors.
  • Director Haas exercised derivative options (non-cash) before selling, a common pattern for tax planning.

Financial Impact

~$1.95M in open-market sales, negligible relative to $5.1B market cap

insider ownership

Risk Factors

  • None from this cluster; however, continued director selling at higher volumes could signal reduced confidence.
  • LGND's stock is near $250; any unexpected negative catalyst (e.g., pipeline setback) could amplify selling.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
93% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-LGND-1781572048043

US Market Status

Market Closed · Opens in 9h 27m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 15, 2026